We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
Read MoreHide Full Article
Catalyst Pharmaceuticals (CPRX - Free Report) will report its third-quarter 2022 results on Nov 9, after the market close.
Catalyst Pharmaceuticals’ earnings surprise history has been mixed so far. The company’s earnings missed expectations in two of the trailing four quarters, beat the same in one and were in line with the estimates in the remaining occasion. Catalyst has a negative earnings surprise of 5.41%. In the last reported quarter, Catalyst delivered a positive earnings surprise of 17.65%.
Shares of Catalyst have returned 107.7% so far this year against the industry’s 32.7% decline.
Image Source: Zacks Investment Research
Let's see how things are shaping up for this announcement.
Factors to Consider
Catalyst’s third-quarter revenues are expected to have been driven by the sales of the only approved drug in its portfolio, Firdapse, for treating Lambert-Eaton myasthenic syndrome (LEMS), and also as a result for patients transitioning from Ruzurgi to Firdapse, after the dispute settlement with Jacobus Pharmaceuticals in July 2022.
Later in September, the company announced that the FDA approved its supplemental new drug application (“sNDA”) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS.
Post the sNDA’s approval by the FDA, Firdapse is now a treatment option in the United States for all LEMS patients beyond six years of age.
This is likely to have boosted the company’s revenues in the to-be-reported quarter.
In December 2021, Catalyst inked a license agreement with DyDo Pharma to develop and commercialize Firdapse in Japan. Dydo has already initiated a phase III study evaluating Firdapse for LEMS in Japan.
The company’s efforts to expand its footprint beyond the United States and conduct additional studies to gain regulatory approvals might have increased its research and development expenses in the third quarter 2022.
Earnings Whisper
Our proven model does not conclusively predict an earnings beat for Catalyst this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below.
Earnings ESP:Catalyst has an Earnings ESP of 0.00%, as the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 19 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Esperion Therapeutics (ESPR - Free Report) has an Earnings ESP of +0.05% and a Zacks Rank #2.
ESPR’s stock has skyrocketed 71.2% this year so far. ESPR beat earnings estimates in three of the trailing four quarters, missing the same in one. It has an earnings surprise of 7.30%, on average.
Jazz Pharmaceuticals (JAZZ - Free Report) has an Earnings ESP of +2.12% and a Zacks Rank #3.
Jazz’s stock has returned 15% in the year so far. JAZZ beat earnings expectations in three of the trailing four quarters while missing the same in one, the average surprise being 10.94%.
IntraCellular Therapies (ITCI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2.
IntraCellular has declined 2.2% in the year so far. ITCI’s earnings beat estimates in two of the trailing four quarters, were in line in one and missed the same in the remaining occasion, the average surprise being 8.35%.
Image: Bigstock
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
Catalyst Pharmaceuticals (CPRX - Free Report) will report its third-quarter 2022 results on Nov 9, after the market close.
Catalyst Pharmaceuticals’ earnings surprise history has been mixed so far. The company’s earnings missed expectations in two of the trailing four quarters, beat the same in one and were in line with the estimates in the remaining occasion. Catalyst has a negative earnings surprise of 5.41%. In the last reported quarter, Catalyst delivered a positive earnings surprise of 17.65%.
Shares of Catalyst have returned 107.7% so far this year against the industry’s 32.7% decline.
Image Source: Zacks Investment Research
Let's see how things are shaping up for this announcement.
Factors to Consider
Catalyst’s third-quarter revenues are expected to have been driven by the sales of the only approved drug in its portfolio, Firdapse, for treating Lambert-Eaton myasthenic syndrome (LEMS), and also as a result for patients transitioning from Ruzurgi to Firdapse, after the dispute settlement with Jacobus Pharmaceuticals in July 2022.
Later in September, the company announced that the FDA approved its supplemental new drug application (“sNDA”) for Firdapse (amifampridine) tablets in 10 mg dosage to include pediatric patients (six years and older) for treating LEMS.
Post the sNDA’s approval by the FDA, Firdapse is now a treatment option in the United States for all LEMS patients beyond six years of age.
This is likely to have boosted the company’s revenues in the to-be-reported quarter.
In December 2021, Catalyst inked a license agreement with DyDo Pharma to develop and commercialize Firdapse in Japan. Dydo has already initiated a phase III study evaluating Firdapse for LEMS in Japan.
The company’s efforts to expand its footprint beyond the United States and conduct additional studies to gain regulatory approvals might have increased its research and development expenses in the third quarter 2022.
Earnings Whisper
Our proven model does not conclusively predict an earnings beat for Catalyst this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below.
Earnings ESP:Catalyst has an Earnings ESP of 0.00%, as the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 19 cents per share. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: Catalyst has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Catalyst Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Catalyst Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Catalyst Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Esperion Therapeutics (ESPR - Free Report) has an Earnings ESP of +0.05% and a Zacks Rank #2.
ESPR’s stock has skyrocketed 71.2% this year so far. ESPR beat earnings estimates in three of the trailing four quarters, missing the same in one. It has an earnings surprise of 7.30%, on average.
Jazz Pharmaceuticals (JAZZ - Free Report) has an Earnings ESP of +2.12% and a Zacks Rank #3.
Jazz’s stock has returned 15% in the year so far. JAZZ beat earnings expectations in three of the trailing four quarters while missing the same in one, the average surprise being 10.94%.
IntraCellular Therapies (ITCI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2.
IntraCellular has declined 2.2% in the year so far. ITCI’s earnings beat estimates in two of the trailing four quarters, were in line in one and missed the same in the remaining occasion, the average surprise being 8.35%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.